OncoCyte Corp expected to post a loss of 9 cents a share - Earnings Preview

Insight Molecular Diagnostics

31/03/2023 13:36

* OncoCyte Corp  OCX.OQ   OCX.O  is expected to show a fall
in
quarterly revenue when it reports  results on April 3. 
    * The Irvine California-based  company is expected to report
 a
60.3% decrease in revenue to $1.424 million from $3.59 million a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for OncoCyte Corp is
for a
loss of 9 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$0.75​, above​ its last closing price of $0.28. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.11       -0.11      -0.08     Beat    29.1
 Jun. 30 2022  -0.12       -0.12      -0.07     Beat    41.3
 Mar. 31 2022  -0.12       -0.12      -0.11     Beat    8.3​
 Dec. 31 2021  -0.14       -0.13      -0.12     Beat    5.6
 ​​Sep.        -0.12       -0.12      -0.15     Missed  -29.3
 30 2021                                                
 Jun. 30 2021  -0.09       -0.10      -0.12     Missed  -20​
 Mar. 31 2021  -0.11       -0.10      -0.05     Beat    50
 Dec. 31 2020  -0.12       -0.11      -0.09     Beat    18.2
 This summary was machine generated March 31 at 12:36 GMT.  All
figures in US dollars  unless otherwise stated